Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for cough and sputum biomarkers in idiopathic pulmonary fibrosis
2010-023828-24Phase 3Terminated
- Sponsor
- University of Nottingham
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of thalidomide in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by University of Nottingham. Primary endpoints: Change in sputum biomarkers, Change in blood biomarkers and 1 more. Started Apr 2011; status: terminated.
02
Drugs
thalidomide
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2010-023828-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023828-24.